-
Benzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More
Monday, August 22, 2016 - 9:07am | 708Read More...Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, including ophthalmology, urology, otolaryngology and infectious diseases. Benzinga had the privilege of chatting with the company's CEO, Mark Baum, about its most recent...
-
AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating
Monday, August 8, 2016 - 1:23pm | 314Read More...David Toung and Casey Meyers, analysts at Argus Research, reaffirmed a Buy rating on AbbVie Inc (NYSE: ABBV) on Monday with an $85 price target following the company's "strong" second quarter earnings print. The analysts noted that not only were AbbVie's results driven by sales of Humira and...
-
Importance Of Phase 1 Trials
Friday, July 22, 2016 - 2:18pm | 458Read More...Pharmaceutical companies are naturally in the business of selling a drug or therapy to patients suffering from an illness in disease. The process is often lengthy, expensive and could result in companies declaring bankruptcies — or reaping hundreds of millions of dollars in profit. For very...
-
Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray
Friday, May 20, 2016 - 9:13am | 257Read More...Shares of Acorda Therapeutics Inc (NASDAQ: ACOR) were trading lower by 2 percent early Friday, but have since recovered most of the losses. The brief selloff occurred in reaction to the company's announcement that it will discontinue development for its Nasal Spray called Plumiaz. Plumiaz...
-
Regeneron Gains 4% Following Q1 Earnings Release
Thursday, May 5, 2016 - 8:53am | 348Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 4 percent early Thursday morning after the company reported its first-quarter results. Regeneron said that it earned $2.57 per share in the first quarter on revenue of $1.2 billion. Wall Street analysts were...
-
B. Riley Cuts Perrigo's Price Target From $146 To $113 On Papa's Exit, FY16 Guidance
Monday, April 25, 2016 - 4:04pm | 277Read More...Linda Bolton Weiser of B. Riley maintains a Neutral rating on Perrigo Company plc Ordinary Shares (NYSE: PRGO), but slashed the stock's price target to $113 per share from a previous $146 price target. The analyst's revised price target was attributed to Perrigo's "...
-
Pharma Names Under Pressure Amid Perrigo Warning
Monday, April 25, 2016 - 1:53pm | 290Read More...Shares of Perrigo Company plc (NYSE: PRGO) plunged more than 15 percent on Monday and hit a new 52-week low after the company appointed John T. Hendrickson as CEO and provided preliminary first quarter results in addition to full year 2016 guidance. Henrdickson was named as CEO following the...
-
Allergan Announces Acquisition Of Topokine Therapeutics, Highlights Fat Reduction Development Program
Friday, April 22, 2016 - 9:56am | 362Read More...Allergan plc (NYSE: AGN) announced on Thursday it has entered into an agreement to acquire Topokine Therapeutics, a privately held, clinical-stage biotechnology that focuses on the development of topical medicines for fat reduction. As part of the agreement, Allergan made an up-font payment of $85...
-
Kite Pharma Gains 2% After Management Provides Update To A Phase 1 Study
Wednesday, April 20, 2016 - 8:38am | 366Read More...Shares of Kite Pharma Inc (NASDAQ: KITE) were trading higher by more than 2 percent early Wednesday morning after the company's management provided an update on an ongoing Phase 1 trial at an industry conference. Kite Pharma's management spoke at the American Association of Cancer Research's annual...
-
This Explains Horizon Pharma's 25% Plunge
Tuesday, April 12, 2016 - 2:00pm | 127Read More...Shares of Horizon Pharma PLC (NASDAQ: HZNP) plunged more than 25 percent on Tuesday after the company released an investor presentation which included revenue outlook. Horizon Pharma said it expects its 2016 revenue to be in a range of $1.025 billion to $1.05 billion and adjusted EBITDA to be...
-
Biogen's Stock Pops Following Better-Than-Expected Q4 Results
Wednesday, January 27, 2016 - 9:37am | 399Read More...Shares of Biogen Inc (NASDAQ: BIIB) were trading higher by more than 5 percent early Wednesday morning after the company reported its fourth quarter and full year results. Biogen earned $4.50 per share in the fourth quarter on revenue of $2.839 billion. Wall Street analysts were expecting the...
-
Relypsa Up 10% Following Encouraging Phase 1 Study Results
Tuesday, January 26, 2016 - 9:30am | 262Read More...Shares of Relypsa Inc (NASDAQ: RLYP), a biopharmaceutical company that focuses on non-absorbed polymeric drugs to tread disorders in the areas of renal, cardiovascular and metabolic diseases, were trading higher by more than 10 percent early Tuesday morning. Relypsa announced after Monday's close...
-
Shares Of Catabasis Pharmaceuticals See-Saw Following Results Of Duchenne Muscular Dystrophy Study
Monday, January 25, 2016 - 2:15pm | 218Read More...Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB), a clinical-stage small-cap biopharmaceutical company, were highly volatile during Monday's trading session after the company
-
Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share
Friday, January 22, 2016 - 2:39pm | 169Read More...Shares of Agile Therapeutics Inc (NASDAQ: AGRX) plunged to a 52-week low of $6.01 on Friday after the company announced a public offering of 5.512 million shares of its common stock at a price of $6.35 per share. Agile Therapeutics' stock closed at $7.06 on Thursday. The company disclosed...
-
Vetr Top Raters Upgrade Mannkind To 4.5-Star Stock
Wednesday, January 20, 2016 - 11:31am | 224Read More...Shares of MannKind Corporation (NASDAQ: MNKD) have lost nearly 50 percent of its value since the start of 2016 and are lower by more than 85 percent over the past year. Despite the large losses over the past year, the Vetr crowd is bullish on the stock's outlook as its rating was upgraded...
